TScan Therapeutics, Inc.

TCRX · Healthcare

$0.67

Capitalizzazione: 45.16M USDRendimento da dividendo: —
AdvanceÈ un buon momento per comprare TScan Therapeutics, Inc.? Chiedi a Copenvest AIOttieni un'analisi Advance con AI su timing, rischio e cosa fanno gli investitori tracciati.Chiedi a Copenvest AI

Caricamento grafico…

Notizie

Ultime notizie su questo titolo

BioPharma Dive4 set 2026, 09:00

Ionis’ rare neurology drug approved; Pfizer inks an ADC deal

InvestorsHub2 set 2026, 12:30

TScan Therapeutics Cuts Workforce by 75% and Shifts Focus to Solid Tumor Program

GlobeNewswire2 set 2026, 11:00

TScan Therapeutics Announces Strategic Reorganization to Focus on in vivo Cell Therapy for Solid Tumors

Simply Wall St.26 ago 2026, 19:08

Why Is Amgen (AMGN) Ending Its Crohn's Disease Research Partnership?

Zacks12 ago 2026, 12:10

TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Misses Revenue Estimates